Asymmetric dimethylarginine (ADMA) accelerates cell senescence

Area of Science:

• Cardiovascular Biology
• Cellular Aging
• Endothelial Function

Background:

• Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor linked to cardiovascular disease.
• Endothelial cell senescence plays a critical role in vascular aging and disease pathogenesis.

Purpose of the Study:

• To investigate the impact of ADMA on endothelial cell senescence.
• To elucidate the mechanisms underlying ADMA-induced endothelial aging.

Main Methods:

• Endothelial cells were cultured and treated with ADMA across multiple passages.
• Assessed senescence markers (beta-galactosidase, telomere length, telomerase activity).
• Measured oxidative stress markers, nitric oxide synthesis, and inflammatory cytokine secretion.

Main Results:

• ADMA significantly accelerated endothelial cell senescence, evidenced by increased beta-galactosidase activity and shortened telomeres.
• ADMA treatment led to increased oxidative stress (allantoin, ROS) and decreased nitric oxide synthesis.
• ADMA reduced dimethylarginine dimethylaminohydrolase activity and increased inflammatory markers (MCP-1, IL-8).

Conclusions:

• ADMA accelerates endothelial cell senescence, likely through increased oxidative stress and reduced nitric oxide bioavailability.
• Modest increases in intracellular ADMA levels significantly impact endothelial aging.
• These findings highlight ADMA as a potential therapeutic target for age-related vascular dysfunction.